Results 61 to 70 of about 876 (115)

Small Molecule Inhibition of Mononegavirales RNA Polymerases

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT The order Mononegavirales includes several non‐segmented negative‐sense RNA viruses that are significant human pathogens, whose transcription and replication depend on multifunctional RNA‐dependent RNA polymerase (L protein). Recent discoveries in cryo‐electron microscopy (cryo‐EM) have elucidated the structures of these polymerases and their ...
Claire R. Cao, Meer Mohammed, Ge Yang, Dong Wang   +3 more
wiley   +1 more source

Favipiravir tautomerism: a theoretical insight [PDF]

Theoretical Chemistry Accounts, 2020
There is no experimental information about the tautomerism of Favipiravir (T-705). Therefore, its tautomeric state was predicted by using density functional theory in gas phase and in solution (toluene, acetonitrile and water). The results have shown that, in neutral state, the enol form is strongly dominating in both gas phase and solution.
openaire   +2 more sources

Chitosan–Alginate Polyelectrolyte Systems: From Classical Release Models to the D‐PARMO Framework

Macromolecular Materials and Engineering, Volume 311, Issue 5, May 2026.
Classical empirical models fail to predict the dynamic in vivo behavior of chitosan‐alginate nanocarriers. Bridging this translational gap, the novel D‐PARMO framework replaces purely descriptive curve‐fitting with a mechanistically informed operational model.
Parastoo Rekab, Akeem Adeyemi Oladipo
wiley   +1 more source

Different SARS‐CoV‐2 Subvariants and Coagulation Markers Trend: A Retrospective Multicentric Study From Iranian Network for Research in Viral Diseases (INRVD)

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims This study aims to examine the prevalence and progression of coagulation disorders in adult COVID‐19 patients and evaluate the effect of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) on coagulation markers. Methods This retrospective study included 1885 hospitalized COVID‐19 patients, aged 20 to over 90 years,
Alireza Razavi, Masoud Pourghahramani Koltapeh, Tina Nazari, Arefe Morvaridi, Behrooz Banivaheb, Sepideh Saeb, Melina Moulaeian, Alireza Zakaryaei, Arash Sabzalian, Maedeh Raei, Bahar Razavi, Saeed Motlaghzadeh, Somayeh Sadat Hosseini, Hassan Karami, Parsa Ghafari, Amir Aboofazeli, Sogol Nastarvand, Negin Kaseb navaz Sarabi, Alex Avakian, Sara Ebadinejad, Tara Keyhani, Parand Danafar, Rozhin Rahimlou, Sedigheh Heidarian, Mozhgan Mondeali, Fatemeh Nafe‐Monfared, Mobina Jafarpour, Marziyeh Samiee, Fatemeh Birang, Amirhossein Mirzazadeh, Seyed Ariana Feiz Abadi, Khabat Barkhordari, Saba Siavoshi, Mahdi Biklari, Mohammad khodabakhsh, AmirHossein Javadi, Samaneh Mirzaee, Farshideh Didgar, Mostafa Etebari, Saedeh Soltanmohamad, Babak Shahbaz, Ebrahim Kord, Seyed Mohammad Hashemi Shahri, Majid Ebrahimzade, Alireza Ansari Moghaddam, Fariba Shahraki Sanavi, Afagh Moattari, Fahime Edalat, Majid Fardi Sheijani, Mohsen Moghadami, Tofigh Yaghubi, Ali Mojtahedi, Abtin Heidarzadeh, Mohammadreza Naghipour, Maryam Sharifi Luyeh, Pershang Nazemi, Kian Alipasandi, Maryam Albaji, Mahdieh Afzali, Nasim Shokouhi, Akram Ezani, Hamid reza Najari, Mirshamsedin Hosseini, Arefeh Ghobadi, Abdoalmabood Momeni, Seyedeh Zeinab Fattahi, Mehdi Mohsenzadeh, Mohammad Jafari, Adeleh Azizi, Sajad Pouryousef, Alijan Tabarraei, Abdolvahab Moradi, Sadeghali Azimi, Yousef Yahyapour, Masoumeh Bayani, Vahdat Poortahmasebi, Mojtaba Varshochi, Masood Ziaee, Shokouh Ghafari, Davod Javanmard, Alireza Soleimani, Sayed‐Hamidreza Mozhgani, Zakiye Mokhames, Zohreh Akhoundimeybodi, Akram Astani, Alireza Abdollahi, Azar Hadadi, Mohammad reza Salehi, Mahboubeh Hajiabdolbaghi, Seyed Reza Raeeskarami, Samira kafan, Mahnaz Montazeri, Marzieh Pazoki, Taghi Riahi, Mahshid Talebi‐Taher, Angila Ataei‐Pirkooh, Farah Bokharaei‐Salim, Seyed Hamid Reza Faiz, Saeed Kalantari, Zeinab Yasin, Seyed Mohammad Jazayeri   +100 more
wiley   +1 more source

Antivirals Targeting Coronavirus RNA‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID‐19 Clinical Trials

Microbial Biotechnology, Volume 19, Issue 4, April 2026.
The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley   +1 more source

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease

Viruses
Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013 ...
Dylan M. Johnson, Terry Juelich, Lihong Zhang, Jennifer K. Smith, Birte K. Kalveram, David Perez, Jeanon Smith, Michael R. Grimes, Tania Garron, Maricela Torres, Shane Massey, Trevor Brasel, David W. C. Beasley, Alex N. Freiberg, Jason E. Comer   +14 more
doaj   +1 more source

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

Advanced Functional Materials, Volume 36, Issue 26, 30 March 2026.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras, Imelda Raczkiewicz, Peggy Bouquet, Jean‐Philippe Dacquin, Jeremy Dhainaut, Anne Goffard, Christophe Volkringer   +6 more
wiley   +1 more source

Favipiravir. [PDF]

The Journal of the Association of Physicians of India, 2020
Agam, Vora, Mangesh, Tiwaskar
openaire   +3 more sources

Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)

Pneumonia
Purpose To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia. Methods A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID ...
Juan P. Horcajada, Rebeca Aldonza, Mónica Real, Silvia Castañeda-Espinosa, Elena Sendra, Joan Gomez-Junyent, Inmaculada López-Montesinos, Silvia Gómez-Zorrilla, Silvia Briansó, Montserrat Duran-Taberna, Andrés Fernández, Cristina Tarragó, Teresa Auguet-Quintillá, the COVID-MAR Research group, the COVID-HJ23 group   +14 more
doaj   +1 more source

Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)

Разработка и регистрация лекарственных средств
Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses antiviral properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2).
T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, A. V. Taganov, I. E. Shohin   +9 more
doaj   +1 more source